A Study of the Novel Drug Dimebon in Patients With Huntington's Disease (DIMOND)

Medivation

Status and phase: Completed; Phase 2

Conditions: Huntington's Disease

Treatments: Drug: Dimebon; Other: Placebo

Study type: Interventional

Funder types: NETWORK; Industry

Identifiers

NCT00497159

DIM05

Details and patient eligibility

About

This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease.

Enrollment: 91 patients

Sex: All

Ages: 29+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical features of HD and a confirmatory family history of HD, and/or genetically confirmed HD;
• Able to take medication (capsules) by mouth.

Exclusion criteria

• Clinical evidence of unstable medical illness;
• Females who are pregnant or lactating or who intend to become pregnant during the study period.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

91 participants in 2 patient groups, including a placebo group

1

Placebo Comparator group

Description:

Placebo

Treatment:

Other: Placebo

2

Experimental group

Description:

Dimebon

Treatment:

Drug: Dimebon